PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.
Evidence
The 70-gene Signature as a Response Predictor for Neoadjuvant Chemotherapy in Breast Cancer
PUBLICATION: Breast Cancer Res Treat. 2010 Feb;119(3):551-8. doi: 10.1007/s10549-009-0333-1. Epub 2009 Feb 13. AUTHORS: Straver M.E., Glas A.M., Hannemann J., Wesseling J., van de Vijver M.J., Rutgers E.J., Vrancken Peeters M.J., van Tinteren H., Van't Veer L.J., Rodenhuis S. SUMMARY: 144 (86%) were having a poor and 23 (14%) a Read More
Clinical Utility of the 70-gene MammaPrint Profile in a Japanese Population
PUBLICATION: Japanese Journal of Clinical Oncology, Volume 40, Issue 6, June 2010, Pages 508โ512, https://doi.org/10.1093/jjco/hyp195. AUTHORS: Makoto Ishitobi, Teodora E. Goranova, Yoshifumi Komoike, Kazuyoshi Motomura, Hiroki Koyama, Annuska M. Glas, Ellen van Lienen, Hideo Inaji, Laura J. Van't Veer, Kikuya Kato SUMMARY: A small observational study in a Japanese Cohort Read More
Validation of 70-gene Prognosis Signature in Node-Negative Breast Cancer
PUBLICATION: Breast Cancer Res Treat. 2009 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub 2008 Sep 26. AUTHORS: Bueno-de-Mesquita J.M., Linn S.C., Keijzer R., Wesseling J., Nuyten D.S., van Krimpen C., Meijers C., de Graaf P.W., Bos M.M., Hart A.A., Rutgers E.J., Peterse J.L., Halfwerk H., de Groot R., Pronk A., Floore A.N., Glas Read More
The 70-gene Prognosis Signature Predicts Early Metastasis in Breast Cancer Patients Between 55 and 70 Years of Age
PUBLICATION: Ann Oncol. 2010 Apr;21(4):717-22. doi: 10.1093/annonc/mdp388. Epub 2009 Oct 13. AUTHORS: Mook S., Schmidt M.K., Weigelt B., Kreike B., Eekhout I., van de Vijver M.J., Glas A.M., Floore A., Rutgers E.J., van 't Veer L.J. SUMMARY: The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 Read More
Gene Expression Profiling in Breast Cancer โ Design of a Pooled Database to Address Open Questions
PUBLICATION: Eur Surg (2009) 41: 221. https://doi.org/10.1007/s10353-009-0487-4. AUTHORS: M. Knauer, E. Wenzl, E.J.T. Rutgers, S.C. Linn, L.J. van't Veer SUMMARY: A pooled database was constructed containing clinical, pathological and microarray data of 1696 patients. The database will be used to study the performance of the 70-gene profile in patients with Read More
A Gene Expression Profile for Detection of Sufficient Tumour Cells in Breast Tumour Tissue: Microarray Diagnosis Eligibility
PUBLICATION: BMC Med Genomics. 2009 Aug 12;2:52. doi: 10.1186/1755-8794-2-52. AUTHORS: Roepman P., Schuurman A., Delahaye L.J., Witteveen A.T., Floore A.N., Glas A.M. SUMMARY: The developed 13-gene profile provides an objective tool for assessment whether a breast cancer sample contains sufficient tumour cells for microarray diagnostics. Read more: A Gene-Expression Profile... Read More
The 70-gene Prognosis-Signature Predicts Disease Outcome in Breast Cancer Patients with 1-3 Positive Lymph Nodes in an Independent Validation Study
PUBLICATION: Breast Cancer Res Treat. 2009 Jul;116(2):295-302. doi: 10.1007/s10549-008-0130-2. Epub 2008 Jul 27. AUTHORS: Mook S., Schmidt M.K., Viale G., Pruneri G., Eekhout I., Floore A., Glas A.M., Bogaerts J., Cardoso F., Piccart-Gebhart M.J., Rutgers E.T., Van't Veer L.J.; TRANSBIG Consortium. SUMMARY: Among 1-3 LN+ patients, the 10-year distant metastasis-free Read More
